Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1

BACKGROUND: Gliomas are the most common primary brain tumors. High-Grade Gliomas have a median survival (MS) of 18 months, while Low-Grade Gliomas (LGGs) have an MS of approximately 7.3 years. Seventy-six percent of patients with LGG express mutated isocitrate dehydrogenase (mIDH) enzyme. Survival o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurooncol Adv
Hauptverfasser: Alghamri, Mahmoud S, Thalla, Rohit, Avvari, Ruthvik P, Dabaja, Ali, Taher, Ayman, Zhao, Lili, Ulintz, Peter J, Castro, Maria G, Lowenstein, Pedro R
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2020
Schlagworte:
Basic and Translational Investigations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212865/
https://ncbi.nlm.nih.gov/pubmed/32642696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa042
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge